Connect
MJA
MJA

Risks of proton-pump inhibitors: what every doctor should know

Francisco J Fernández-Fernández, Gonzalo Pía and Pascual Sesma
Med J Aust 2009; 190 (11): . || doi: 10.5694/j.1326-5377.2009.tb02605.x
Published online: 1 June 2009

To the Editor: We read with interest Talley’s excellent and informative editorial about the risks associated with proton-pump inhibitors (PPIs).1 Other possible serious side effects of PPIs that need to be taken into account are potential drug interactions with aspirin and clopidogrel.


  • Internal Medicine, Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain.


Correspondence: fjf-fernandez@terra.es

  • 1. Talley NJ. Risks of proton-pump inhibitors: what every doctor should know [editorial]. Med J Aust 2009; 190: 109-110. <MJA full text>
  • 2. Fernández-Fernández FJ. Might proton pump inhibitors prevent the antiplatelet effects of low- or very low-dose aspirin [letter]? Arch Intern Med 2002; 162: 2248.
  • 3. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236-242.
  • 4. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Jan 28. [Epub ahead of print].

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.